Objective In the management of chronic gout, a large proportion of patients need long-term
management with urate lowering therapy (ULT). This study reviews medication adherence to …

Introduction Reported adherence to urate-lowering therapy (ULT) in gout varies widely (17%–
83.5%). Variability may partly be due to different adherence measurement methods. This …

Background: Adherence to tuberculosis (TB) drugs is one of the key aspects of global TB
control, yet there is a lack of epidemiological evidence on the factors influencing adherence …

Objectives To discover differential metabolites and pathways underlying infrequent gout
flares (InGF) and frequent gout flares (FrGF) using metabolomics and establish a predictive …

Objectives When urate lowering therapy is indicated in patients with gout, medication
adherence is essential. This study assesses non-persistence and non-adherence in patients …

Gout is the most common form of inflammatory arthritis worldwide and is characterized by
painful recurrent flares of inflammatory arthritis that are associated with a transiently …

Objective Initiating urate‐lowering therapy (ULT) in gout can precipitate arthritis flares. There
have been limited comparisons of flare risk during the initiation and escalation of allopurinol …

Introduction/objectives Lifelong urate-lowering therapy (ULT) with xanthine oxidase
inhibitors (XOIs), such as allopurinol and febuxostat, is the cornerstone of gout treatment …

Objective To determine whether lowering serum uric acid level (sUA) to below 6 mg/dL
(target) improves mild to moderate chronic kidney disease (CKD) and whether CKD stage …

The aim of the study was to investigate the longitudinal transition trajectory of gout and its
comorbidities in male patients with gout in different age groups. A total of 3973 male patients …